Advice
Following a full submission.
Sildenafil citrate (Revatio) is accepted for restricted use within NHS Scotland for the treatment of patients with pulmonary arterial hypertension classified as WHO functional class III, to improve exercise capacity.
This is an orphan indication for sildenafil with limited clinical evidence from short-term clinical trials. It is restricted to initiation by specialists working in the Scottish Pulmonary Vascular Unit and by physicians experienced in the management of pulmonary vascular disease.
Download detailed advice48KB (PDF)
Medicine details
- Medicine name:
- Sildenafil citrate 20mg tablets (Revatio®)
- SMC ID:
- 235/06
- Indication:
- Pulmonary arterial hypertension
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 13 February 2006